What Should Investors Know About Catalent (CTLT) Stock?

By Chris Stiles • Tuesday, December 19 16:58 • Permanent Link

Shares of Pharmaceutical company Catalent jumped 6.6% today. With many investors piling into CTLT without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Catalent has moved -5.6% over the last year, and the S&P 500 logged a change of 24.0%
CTLT has an average analyst rating of buy and is -8.09% away from its mean target price of $48.57 per share
Its trailing earnings per share (EPS) is $-5.61
Catalent has a trailing 12 month Price to Earnings (P/E) ratio of -8.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $1.62 and its forward P/E ratio is 27.6
The company has a Price to Book (P/B) ratio of 2.1 in contrast to the S&P 500's average ratio of 2.95
Catalent is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-69375000, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.